Form 4: Syra Health Director Avutu Reddy Acquires Stock Options
Insider Transaction Report
Syra Health Corp. Director Avutu Reddy acquired 43,348 stock options with a $0.07 exercise price, vesting over three years.
Summary
- Avutu Reddy, a Director and 10% Owner of Syra Health Corp. (SYRA), acquired 43,348 stock options.
- The options have an exercise price of $0.07 per share.
- The transaction date for the acquisition was November 21, 2025.
- These options were issued under the Issuer's 2022 Omnibus Equity Incentive Plan.
- The options will vest in three tranches: one-third on December 31, 2025, and the remaining two-thirds in equal amounts on December 31, 2026, and December 31, 2027.
- The options have an expiration date of November 21, 2035.
- Following this transaction, Avutu Reddy beneficially owns 70,926 derivative securities (stock options).
Sentiment
Score: 7
Explanation: The acquisition of stock options by a director and 10% owner is generally viewed positively as it indicates confidence in the company's future and aligns management's interests with shareholders. The vesting schedule also suggests a long-term commitment.
Positives
- A Director and 10% Owner, Avutu Reddy, acquired additional stock options, which can signal confidence in the company's future performance.
- The options were issued under an established 2022 Omnibus Equity Incentive Plan, indicating a structured approach to executive compensation and alignment with shareholder interests.
Future Outlook
The vesting schedule for the acquired options, extending through December 2027, indicates a long-term commitment and alignment of the director's interests with the company's future performance and growth.
Industry Context
This filing represents a standard insider transaction where a director increases their equity stake in the company through option grants. Such transactions are common mechanisms for aligning management and director incentives with shareholder value creation, reflecting confidence in the company's strategic direction and future prospects.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Incentive Plan Utilization | Stock options were issued pursuant to the Issuer's 2022 Omnibus Equity Incentive Plan. | 11/21/2025 | This indicates the company is utilizing its established equity compensation framework to incentivize directors and align their interests with long-term shareholder value. |
Stakeholder Impact
- Shareholders may view the director's increased equity stake as a positive signal of management confidence and commitment to the company's long-term success.
- Employees may see this as a reinforcement of the company's equity incentive programs and a sign of stability from leadership.
Next Steps
- Vesting of one-third of the options on December 31, 2025.
- Vesting of remaining options in equal amounts on December 31, 2026, and December 31, 2027.
Key Dates
| Date | Description |
|---|---|
| 11/21/2025 | Date of earliest transaction for the acquisition of stock options. |
| 11/21/2025 | Date the stock options were granted. |
| 11/25/2025 | Date the Form 4 was signed by Avutu S. Reddy. |
| 12/31/2025 | First vesting date for one-third of the acquired stock options. |
| 12/31/2026 | Second vesting date for a portion of the remaining stock options. |
| 12/31/2027 | Third and final vesting date for the remaining stock options. |
| 11/21/2035 | Expiration date of the acquired stock options. |
Keywords
Syra Health Corp, SYRA, Stock Options, Insider Transaction, Form 4, Avutu Reddy, Equity Incentive Plan, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.